载药微球经动脉化疗栓塞治疗大肝癌的临床效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of drug-loaded microspheres transcatheter arterial chemoembolization (DEB-TACE) treating large liver cancer.Methods A retrospective analysis of 73 cases of large liver cancer patients undergoing transarterial arterial chemoembolization admitted to our hospital from January 2017 to January 2019,including 35 cases of drug-loaded microsphere hepatic arterial chemoembolization (DEB-TACE) (observation group),38 cases of traditional hepatic arterial chemoembolization (c-TACE) (control group), laboratory tests were performed before treatment and on days 3 and 7 after treatment, and intensive CT examination was performed before treatment and 1 month after treatment.The imaging data and clinical data were analyzed and summarized to compare the differences in the incidence of tumor response, complications and adverse reactions between the two treatment methods in patients.Results The alanine aminotransferase (ALT) and aspartate aminotransferase (AST) of patients of the two groups on the 3rd and 7th days after treatment were higher than those in this group before treatment,and the differences were statistically significant(P＜0.05).There were no significant differences in ALT and AST between the two groups on the 3rd and 7th days after treatment (P＞0.05).There were no serious adverse reactions in both groups; there were no significant differences in the disease remission rate and disease control rate at 1 month after treatment between two groups (P＞0.05).Conclusion DEB-TACE is safe and effective in the treatment of large liver cancer, and it is worthy of clinical application.

Key words： Liver cancer Hepatic arterty Transarterial chemoembolization Drug-loaded microspheres Treatment effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Zhao-hai
	ZHOU Jian-hui
	LIU Hong-jun

Cite this article:

ZHOU Zhao-hai,ZHOU Jian-hui,LIU Hong-jun. Clinical effect of drug-loaded microspheres transcatheter arterial chemoembolization treating large liver cancer[J]. 中国当代医药, 2020, 27(22): 87-90.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I22/87

[1]	Kishore S，Friedman T，Madoff DC.Update on embolization therapies for hepatocellular carcinoma[J].Curr Oncol Rep，2017，19（6）：40.
[2]	Bruix J，Sherman M.Management of hepatocellular carcinoma[J].Hepatology，2005，42：1208-1236.
[3]	邢冬娟，徐爱民.微球在肝细胞癌经导管肝动脉化疗栓塞术治疗中的应用及研究进展[J].中华肝胆外科杂志，2011，17（12）：1023-1026.
[4]	中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范（2017年版）[J].中华消化外科杂志，2017，16（7）：635-647.
[5]	Lencioni R，Llovet JM.Modified RECIST（mRECIST）assessment for hepatocellular carcinoma[J].Semin Liver Dis，2010，30（1）：52-60.
[6]	邱力戈，胡宝山，李勇，等.HepaSphere 载药微球与碘油化疗栓塞大肝癌的不良反应比较[J].中华介入放射学电子杂志，2018，6（2）：99-103.
[7]	陈猛，陈晓明.2017年载药微球化疗栓塞治疗肝癌临床研究进展[J].循证医学，2018，18（1）：26-28.
[8]	姜松，李桂杰，周祝谦，等.CalliSpheres 载药栓塞微球治疗中晚期肝癌临床效果评价[J].中华介入放射学电子杂志，2017，5（3）：174-178.
[9]	曹国洪，王凯，李佳琪，等.CalliSphere@载药微球经动脉导管化疗栓塞治疗肝癌患者的有效性及安全性分析[J].中国介入影像与治疗，2018，15（1）：42-46.
[10]	陈刚，张鼎，应亚草，等.国产载药微球经动脉化原发性肝癌的临床研究[J].浙江大学学报（医学版），2017，46（1）：44-51.
[11]	Deipolyi AR，Oklu R，A1-Ansari S，et al.Safety and eficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma[J].J Vasc Interv Radiol，2015，26（4）：516-522.
[12]	赵倩，颜志平.载药微球经导管动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志，2017，11（26）：1052-1056.
[13]	郭志，滕皋军，邹英华，等.载药微球治疗原发性和转移性肝癌的技术操作推荐[J].中华放射学杂志，2019，53（5）：336-340.
[14]	段峰，阎洁羽，刘凤永，等.装载阿霉素的DC-Beads 经导管化疗栓塞治疗不可切除性原发性肝癌的初步经验[J].中华肿瘤杂志，2014，36（4）：314-315.
[15]	刘金，曹刚，张根山.国产CalliSpheres 载药微球治疗原发性肝癌12 例[J].介入放射学杂志，2017，26（11）：993-998.
[16]	池琦，张玲玲，刘彬，等.表柔比星分别联合碘油与Hepasphere 载药微球对肝癌患者TACE 的疗效分析[J].现代肿瘤医学，2018，26（13）：2090-2093.
[17]	黄英杰，凌永志，秦梓良，等.HepaSphere 载药微球治疗原发性肝癌的效果评价[J].临床医学，2018，38（1）：35-36.
[18]	聂德红，邵建民，李洪义，等.原发性肝癌TACE 治疗后的影像学评价[J].中国当代医药，2015，22（18）：17-20.